UBS Group’s Citius Pharmaceuticals CTXR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $49.5K | Sell |
55,025
-21,411
| -28% | -$17.3K | ﹤0.01% | 7370 |
|
|
2025
Q4 | $59.4K | Buy |
76,436
+50,523
| +195% | +$63.2K | ﹤0.01% | 7135 |
|
|
2025
Q3 | $32.1K | Sell |
25,913
-167,014
| -87% | -$233K | ﹤0.01% | 7846 |
|
|
2025
Q2 | $307K | Buy |
192,927
+125,712
| +187% | +$115K | ﹤0.01% | 6424 |
|
|
2025
Q1 | $100K | Buy |
67,215
+39,648
| +144% | +$94.9K | ﹤0.01% | 7048 |
|
|
2024
Q4 | $110K | Buy |
27,567
+27,543
| +114,763% | +$186K | ﹤0.01% | 6814 |
|
|
2024
Q3 | $303 | Sell |
24
-2,487
| -99% | -$41.8K | ﹤0.01% | 9009 |
|
|
2024
Q2 | $36.7K | Sell |
2,511
-2,874
| -53% | -$51.5K | ﹤0.01% | 6925 |
|
|
2024
Q1 | $121K | Sell |
5,385
-116
| -2% | -$2.12K | ﹤0.01% | 6132 |
|
|
2023
Q4 | $104K | Buy |
5,501
+1,580
| +40% | +$30K | ﹤0.01% | 6139 |
|
|
2023
Q3 | $67K | Buy |
3,921
+1,076
| +38% | +$25.6K | ﹤0.01% | 6096 |
|
|
2023
Q2 | $85.4K | Buy |
2,845
+2,830
| +18,867% | +$93.2K | ﹤0.01% | 6140 |
|
|
2023
Q1 | $428 | Buy |
+15
| New | +$432 | ﹤0.01% | 9041 |
|
|
2022
Q3 | – | Sell |
-45
| Closed | -$1K | – | 10418 |
|
|
2022
Q2 | $1K | Sell |
45
-924
| -95% | -$25.3K | ﹤0.01% | 9842 |
|
|
2022
Q1 | $43K | Sell |
969
-2,939
| -75% | -$116K | ﹤0.01% | 6638 |
|
|
2021
Q4 | $150K | Buy |
3,908
+1,638
| +72% | +$74.3K | ﹤0.01% | 5934 |
|
|
2021
Q3 | $115K | Buy |
2,270
+386
| +20% | +$19.4K | ﹤0.01% | 5743 |
|
|
2021
Q2 | $164K | Sell |
1,884
-2,636
| -58% | -$158K | ﹤0.01% | 5504 |
|
|
2021
Q1 | $201K | Buy |
4,520
+433
| +11% | +$17.2K | ﹤0.01% | 5480 |
|
|
2020
Q4 | $104K | Buy |
+4,087
| New | +$107K | ﹤0.01% | 5660 |
|
|
2020
Q3 | – | Sell |
-311
| Closed | -$9K | – | 8045 |
|
|
2020
Q2 | $9K | Buy |
+311
| New | +$6.8K | ﹤0.01% | 7069 |
|
|
2019
Q3 | – | Sell |
-146
| Closed | -$4K | – | 8032 |
|
|
2019
Q2 | $4K | Buy |
+146
| New | +$4.16K | ﹤0.01% | 7442 |
|
|
2019
Q1 | – | Sell |
-27
| Closed | -$1K | – | 7780 |
|
|
2018
Q4 | $1K | Buy |
+27
| New | +$924 | ﹤0.01% | 7884 |
|
|
2018
Q3 | – | Sell |
-103
| Closed | -$6K | – | 8013 |
|
|
2018
Q2 | $6K | Sell |
103
-119
| -54% | -$7.91K | ﹤0.01% | 7398 |
|
|
2018
Q1 | $17K | Buy |
222
+162
| +270% | +$14.9K | ﹤0.01% | 6501 |
|
|
2017
Q4 | $6K | Sell |
60
-16
| -21% | -$1.6K | ﹤0.01% | 7290 |
|
|
2017
Q3 | $6K | Buy |
+76
| New | +$5.93K | ﹤0.01% | 7137 |
|
Other funds holding CTXR
VCM
VFT
HF
AAG
UBS Group's CTXR Position: Q1 2026 in Review
UBS Group reduced its Citius Pharmaceuticals (CTXR) stake by 28% in Q1 2026, selling an estimated $17.3K and leaving 55,025 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7370.
UBS Group first reported a position in CTXR in Q3 2017 and has held it in 27 quarters since. The position peaked at $307K in Q2 2025. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.
- UBS Group held 55,025 shares of Citius Pharmaceuticals worth $49.5K as of Q1 2026.
- UBS Group sold 21,411 Citius Pharmaceuticals shares in Q1 2026, an estimated $17.3K.
- Citius Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7370 holding.
- UBS Group first reported a position in Citius Pharmaceuticals in Q3 2017 and has held it in 27 quarters since.
- UBS Group's Citius Pharmaceuticals position peaked at $307K in Q2 2025.
- 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.